ECT-204

N/A

Report date: 2026/05/21 20:00:22

Base Information

Drug NameECT-204
Drug Alias Namean autologous T-cell immunotherapy (ECT204)ARTEMIS®ECT-204JWATM-204ECT204
ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapyCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Lentiviral vector
Mechanisms of ActionT lymphocyte replacementsWnt signalling pathway inhibitorsGlypican-3 inhibitors
TargetsGlypican-3
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungLiver NeoplasmsCarcinoma, Hepatocellular
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesTaiwanMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesEureka Therapeutics IncJw Therapeutics (Shanghai) Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesJw Therapeutics (Shanghai) Co LtdEureka Therapeutics IncShanghai Ming Ju Biotechnology Co Ltd +[4] 
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell LungLiver NeoplasmsCarcinoma, Hepatocellular
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A